Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioharvest Sciences (BHST) Total Non-Current Liabilities (2023 - 2025)

Historic Total Non-Current Liabilities for Bioharvest Sciences (BHST) over the last 3 years, with Q3 2025 value amounting to $14.3 million.

  • Bioharvest Sciences' Total Non-Current Liabilities rose 2133.56% to $14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.3 million, marking a year-over-year increase of 2133.56%. This contributed to the annual value of $9.4 million for FY2024, which is 17783.35% up from last year.
  • Latest data reveals that Bioharvest Sciences reported Total Non-Current Liabilities of $14.3 million as of Q3 2025, which was up 2133.56% from $14.9 million recorded in Q2 2025.
  • Bioharvest Sciences' Total Non-Current Liabilities' 5-year high stood at $14.9 million during Q2 2025, with a 5-year trough of $3.4 million in Q4 2023.
  • Moreover, its 3-year median value for Total Non-Current Liabilities was $10.4 million (2024), whereas its average is $10.4 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first surged by 17783.35% in 2024, then tumbled by 933.81% in 2025.
  • Bioharvest Sciences' Total Non-Current Liabilities (Quarter) stood at $3.4 million in 2023, then surged by 177.83% to $9.4 million in 2024, then surged by 51.52% to $14.3 million in 2025.
  • Its Total Non-Current Liabilities stands at $14.3 million for Q3 2025, versus $14.9 million for Q2 2025 and $8.5 million for Q1 2025.